These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 24125749)

  • 41. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.
    Zhai Y; Iura A; Yeasmin S; Wiese AB; Wu R; Feng Y; Fearon ER; Cho KR
    Oncogene; 2011 Oct; 30(40):4152-62. PubMed ID: 21499300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of R-spondin 1 through activating Wnt/β-catenin in the growth, survival and migration of ovarian cancer cells.
    Liu Q; Zhao Y; Xing H; Li L; Li R; Dai J; Li Q; Fang S
    Gene; 2019 Mar; 689():124-130. PubMed ID: 30572097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A mouse model for endometrioid ovarian cancer arising from the distal oviduct.
    van der Horst PH; van der Zee M; Heijmans-Antonissen C; Jia Y; DeMayo FJ; Lydon JP; van Deurzen CH; Ewing PC; Burger CW; Blok LJ
    Int J Cancer; 2014 Sep; 135(5):1028-37. PubMed ID: 24474556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
    Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
    Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway.
    Hu W; Li M; Chen Y; Gu X
    J Ovarian Res; 2021 Sep; 14(1):121. PubMed ID: 34535173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose.
    García-Jiménez C; García-Martínez JM; Chocarro-Calvo A; De la Vieja A
    J Mol Endocrinol; 2014 Feb; 52(1):R51-66. PubMed ID: 24049067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.
    Barbolina MV; Burkhalter RJ; Stack MS
    Biochem J; 2011 Jul; 437(1):1-12. PubMed ID: 21668411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
    Song L; Li Y; He B; Gong Y
    Clin Colorectal Cancer; 2015 Sep; 14(3):133-45. PubMed ID: 25799881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
    Cai Y; Cai T; Chen Y
    J Cell Biochem; 2014 Apr; 115(4):625-31. PubMed ID: 24190862
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Wnt/β-Catenin Signaling Pathway in Skin Carcinogenesis and Therapy.
    Li J; Ji L; Chen J; Zhang W; Ye Z
    Biomed Res Int; 2015; 2015():964842. PubMed ID: 26078973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
    Boone JD; Arend RC; Johnston BE; Cooper SJ; Gilchrist SA; Oelschlager DK; Grizzle WE; McGwin G; Gangrade A; Straughn JM; Buchsbaum DJ
    Lab Invest; 2016 Feb; 96(2):249-59. PubMed ID: 26658453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Wnt/β-catenin signaling in colorectal cancer: Is therapeutic targeting even possible?
    Disoma C; Zhou Y; Li S; Peng J; Xia Z
    Biochimie; 2022 Apr; 195():39-53. PubMed ID: 35066101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The potential of targeting Wnt/β-catenin in colon cancer.
    Sebio A; Kahn M; Lenz HJ
    Expert Opin Ther Targets; 2014 Jun; 18(6):611-5. PubMed ID: 24702624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line.
    Yen HY; Tsao CW; Lin YW; Kuo CC; Tsao CH; Liu CY
    Sci Rep; 2019 Nov; 9(1):17267. PubMed ID: 31754130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN.
    Tanwar PS; Zhang L; Kaneko-Tarui T; Curley MD; Taketo MM; Rani P; Roberts DJ; Teixeira JM
    PLoS One; 2011; 6(6):e20715. PubMed ID: 21695255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Podoplanin regulates mammary stem cell function and tumorigenesis by potentiating Wnt/β-catenin signaling.
    Bresson L; Faraldo MM; Di-Cicco A; Quintanilla M; Glukhova MA; Deugnier MA
    Development; 2018 Feb; 145(4):. PubMed ID: 29361573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Wnt/beta-catenin signaling pathway as a target in drug discovery.
    Takahashi-Yanaga F; Sasaguri T
    J Pharmacol Sci; 2007 Aug; 104(4):293-302. PubMed ID: 17721040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FAM83A has a pro-tumor function in ovarian cancer by affecting the Akt/Wnt/β-catenin pathway.
    Zhao J; Zhao F; Yang T; Tian S; Zhao M; Wang S; Yang X
    Environ Toxicol; 2022 Apr; 37(4):695-707. PubMed ID: 34931434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Wnt/beta-catenin signal pathway and malignant hematological disease -- review].
    Wang YX; Zhang JH; Gu ZW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):234-7. PubMed ID: 19236787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the Wnt/β-catenin signaling pathway in cancer.
    Zhang Y; Wang X
    J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.